{
    "ticker": "PROK",
    "name": "ProKidney Ltd.",
    "description": "ProKidney Ltd. is a clinical-stage biotechnology company focused on developing groundbreaking treatments for chronic kidney disease (CKD). Founded in 2020, the company aims to address the unmet medical needs of patients suffering from CKD by creating innovative therapies that restore kidney function and improve quality of life. ProKidney\u2019s lead product candidate, REACT, is an advanced cell-based therapy designed to enhance kidney function and has shown promising results in clinical trials. The company is committed to advancing its research and development efforts, leveraging a team of experts in nephrology, cell therapy, and regenerative medicine. With a strong focus on patient outcomes, ProKidney is dedicated to transforming the treatment landscape for CKD and providing hope for millions of patients worldwide. The company\u2019s mission is to improve kidney health and provide effective solutions that can lead to a brighter future for those affected by kidney diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2020",
    "website": "https://www.prokidney.com",
    "ceo": "Michael A. Cummings",
    "social_media": {
        "twitter": "https://twitter.com/ProKidney",
        "linkedin": "https://www.linkedin.com/company/prokidney/"
    },
    "investor_relations": "https://ir.prokidney.com",
    "key_executives": [
        {
            "name": "Michael A. Cummings",
            "position": "CEO"
        },
        {
            "name": "Katherine S. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "REACT"
            ]
        }
    ],
    "seo": {
        "meta_title": "ProKidney Ltd. | Innovative Solutions for Chronic Kidney Disease",
        "meta_description": "Explore ProKidney Ltd., a pioneering biotechnology company focused on developing groundbreaking therapies for chronic kidney disease. Learn about our mission and innovative products.",
        "keywords": [
            "ProKidney",
            "Chronic Kidney Disease",
            "Cell Therapy",
            "Biotechnology",
            "Nephrology"
        ]
    },
    "faq": [
        {
            "question": "What is ProKidney known for?",
            "answer": "ProKidney is known for developing innovative therapies for chronic kidney disease, particularly its lead product candidate REACT."
        },
        {
            "question": "Who is the CEO of ProKidney?",
            "answer": "Michael A. Cummings is the CEO of ProKidney Ltd."
        },
        {
            "question": "Where is ProKidney headquartered?",
            "answer": "ProKidney is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are ProKidney's main products?",
            "answer": "ProKidney's main product is REACT, a cell-based therapy aimed at enhancing kidney function."
        },
        {
            "question": "When was ProKidney founded?",
            "answer": "ProKidney was founded in 2020."
        }
    ],
    "competitors": [
        "CRLBF",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV"
    ]
}